Side-by-side financials for ERNA and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ERNA | LLY |
|---|---|---|
| Market cap | - | $1.070 T |
| US-listed rank | - | #10 |
| Revenue (latest FY) | $582.00K | $65.18B |
| Net income (latest FY) | -$14.08M | $20.64B |
| Net margin | -2419.9% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 1,000 | 989 |
In their latest fiscal years, Eterna Therapeutics Inc. reported $582.00K in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Eterna Therapeutics Inc. and ELI LILLY & Co, or browse the full rankings.